Stockreport

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

G1 Therapeutics, Inc.  (GTHX) 
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: g1therapeutics.com/pages/investors/investors.htm
PDF - Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guida [Read more]